This medication is used to manage the symptoms of migraine headaches, which may present with severe, throbbing pain. The primary therapeutic domain is applied across clinical settings that involve acute or unstable symptom patterns, and is commonly used across conditions presenting with acute episodes.

This medicine is commonly used for the acute symptomatic relief of migraine, and may help address symptom clusters that include throbbing or pulsating pain, photophobia (light sensitivity), phonophobia (sound sensitivity), and associated nausea or vomiting. This comprehensive symptomatic relief supports patients in coping more steadily with difficult manifestations. It is commonly used when symptoms become temporarily overwhelming and short-term symptomatic assistance is needed.

This medicine is used in situations involving acute or disruptive symptom patterns, applied during phases when symptoms become more noticeable. Offering symptomatic relief, it assists with maintaining functional stability and contributes to improved day-to-day comfort during the period of heightened symptoms.

---

Quick Fact: Relief for Acute Symptoms Related to Discomfort Sumatriptan Aurobindo is relevant for easing symptoms associated with a current migraine episode, which may include intense cranial pain and sensory distress.

Regulatory References

1. NIH MedlinePlus Drug Information

Sumatriptan Aurobindo is an acute migraine treatment restricted to use by adults (18 to 65 years old) with a clear diagnosis of migraine. Eligibility for use is strictly defined by regulatory documents, primarily restricting individuals with certain underlying vascular and health conditions.

Contraindicated Populations (Must Not Use)

This medicine is formally contraindicated for patients with:

• A history, symptoms, or signs of Ischemic Heart Disease (IHD), including angina pectoris or prior heart attack.
• Coronary artery vasospasm (Prinzmetal's angina) or Peripheral Vascular Disease.
• A history of stroke, transient ischemic attack (TIA), or hemiplegic or basilar migraine.
• Uncontrolled hypertension or severe hepatic impairment.
• Known hypersensitivity to sumatriptan.
• Concurrent or recent use (within 24 hours) of ergotamine-containing medications or other triptans, or recent use (within two weeks) of a Monoamine Oxidase-A inhibitor (MAOI).

Restricted or Not Recommended Use

Use is not recommended for the following groups due to limited safety and efficacy data:

• Children and adolescents (under 18 years of age).
• Elderly patients (over 65 years of age).

Special consideration is required for patients with a history of seizures or mild to moderate hepatic impairment, where lower doses may be necessary. For women who are breastfeeding, official labeling recommends avoiding nursing for at least 12 hours after treatment.

Interactions with other medicines and products

Contraindicated Combinations and Mandatory Timing Rules

Co-administration of Sumatriptan Aurobindo is formally prohibited with several specific classes of medicines due to documented interaction risks. These combinations include Monoamine Oxidase Inhibitors (MAOIs), ergotamine or ergotamine-type medications (e.g., methysergide), and other 5-HT1 receptor agonists (other triptans). The prohibition of MAOIs is based on a pharmacokinetic interaction, as these medicines inhibit the clearance of sumatriptan, leading to significantly increased plasma concentration and exposure. Conversely, the prohibition of ergotamine and other triptans is based on a pharmacodynamic effect, specifically the risk of additive vasospastic effects.

Strict administration timing rules are required. Sumatriptan must not be administered for two weeks after discontinuing MAOI therapy. Administration of Sumatriptan and ergotamine-containing medicines or other triptans must be separated by a minimum interval of 24 hours.

Other Documented Interactions

Co-administration with Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Noradrenaline Reuptake Inhibitors (SNRIs) carries an officially documented risk of Serotonin Syndrome, based on post-marketing reports of this additive serotonergic effect. Regarding other substances, regulatory documents note that there is no evidence of interaction with alcohol. However, an increased risk of undesirable effects is documented with concomitant use of herbal preparations containing St John’s Wort.

The mechanism of action for Sumatriptan is highly targeted, focusing on key elements of the trigeminovascular system to modulate the specific physiological responses of that system. It operates through the selective activation of specific serotonin receptors, which initiates a dual cascade that alters specific physiological parameters.

Selective Activation of 5-HT1B/1D Receptors

Sumatriptan functions as a selective agonist (activator) for the 5-HT1B and 5-HT1D serotonin receptors. This molecular interaction engages mechanisms that modulate signaling within the neurotransmitter system, thereby modifying the early molecular steps that shape the systemic physiological outcomes.

Modulation of Vascular Tone and Neurogenic Signaling

Activation of the 5-HT1B receptors on the smooth muscle of intracranial blood vessels causes selective vasoconstriction. Concurrently, 5-HT1D receptor activation on presynaptic nerve endings inhibits the peripheral release of pro-inflammatory neuropeptides (like CGRP). This action alters specific signaling patterns and reduces the release of excessive mediator activity, which contributes to pathway modulation.

Suppression of the Pathological Cascade

The resulting physiological effect is the direct and simultaneous suppression of vessel dilation and neurogenic inflammation. This combined action influences feedback regulation within the pathway, resulting in the suppression of afferent nociceptive signal transmission from the periphery.

How to Use Sumatriptan Aurobindo

Sumatriptan Aurobindo is a medicine for the acute treatment of migraine headaches, and its usage is strictly defined by regulatory guidelines. The medicine is administered through the oral route as a film-coated tablet, and it is not intended for use in preventing migraine attacks.

Official Administration Protocol

The medicine is designed to be taken as soon as symptoms appear or at any point during a migraine attack. The tablet must be swallowed whole with liquid and may be taken with or without food.

Standard Dosing and Frequency

Usage is restricted by a maximum dose and required time intervals between doses. Dosing must follow these specific regulatory constraints:

Dosing Parameter	Official Constraint
Standard Single Dose Range	25 mg, 50 mg, or 100 mg
Maximum Single Dose	100 mg
Maximum 24-Hour Dose	200 mg
Minimum Inter-Dose Interval	2 hours

If the initial dose is entirely ineffective for the attack, a second dose should not be taken for that same episode. If the migraine returns after initial relief, a second dose may be taken, provided the minimum 2-hour interval has elapsed.

Population-Specific Use Rules

Official labeling includes specific restrictions for certain populations. For patients with mild to moderate hepatic impairment, the maximum single dose is limited to 50 mg. The safety and efficacy of the tablet form have not been established for individuals under 18 years of age.

Research Evidence / Overview of Studies

Research on Sumatriptan has primarily examined its use in the acute treatment of migraine attacks in adults, with a focus on its administration profile and whether changes were observed in various disease metrics.

---

Mechanism and Initial Findings

Sumatriptan belongs to the triptan class of medications. Research has explored the drug's interaction with the serotonin receptors (specifically 5 HT1 B and 5 HT1 D), which are believed to be involved in migraine pathways. Some studies have investigated whether this activity is associated with changes in symptoms during a migraine attack.

---

Clinical Outcomes and Comparison

A large body of evidence, including multiple randomized controlled trials (RCTs), has been collected to evaluate changes in participant symptoms following the use of sumatriptan. These studies generally found that a single dose of sumatriptan surpassed placebo in outcomes related to pain relief.

Key Findings from Meta-Analyses:

• Pain-Free Status: In major analyses of the oral 100 mg dose, approximately 3 in 10 people (32%) achieved pain-free status within two hours, compared with about 1 in 10 (11%) taking placebo.
• Headache Relief: About 6 in 10 people (61%) taking sumatriptan 100 mg reported headache relief (pain reduced to mild or none) within two hours, versus 3 in 10 (32%) taking placebo.
• Associated Symptoms: Studies also evaluated the relief of associated symptoms, such as nausea and sensitivity to light and sound (photophobia and phonophobia), with approximately half of the participants reporting relief of these symptoms within two hours.

Safety and Tolerability

Data from these trials indicated that adverse events were generally of short duration and mild to moderate in severity. The adverse events reported most frequently in study participants were documented, including examples such as gastrointestinal events and temporary injection-site reactions (where applicable).

Common questions about Sumatriptan Aurobindo (FAQ)

Q: Is Sumatriptan Aurobindo the same as other sumatriptan brands?

A: Sumatriptan Aurobindo contains the same active ingredient, sumatriptan, as other brands. Regulatory bodies classify it as a generic medicine. Generic products are required to demonstrate bioequivalence to their brand-name counterparts, meaning they are intended to be interchangeable and contain the same active ingredient.

Q: How quickly does Sumatriptan Aurobindo start to work?

A: Official studies on the oral tablet formulation have examined the time to relief. Research indicates that many participants begin to experience an effect, such as headache relief, within approximately two hours of taking the dose. Individual response times may vary.

Q: What should I expect the first time I take Sumatriptan Aurobindo?

A: Official documents list several common, often transient, experiences that can occur shortly after administration. These may include feelings of flushing (warmth or redness), tingling (paresthesia), or sensations of pain, pressure, or tightness in the chest, throat, neck, or jaw. These effects are typically transient.

Q: Is it common to feel tingling or flushing after taking this medicine?

A: Yes, regulatory labeling classifies these as common side effects. Sensations such as tingling or prickling (paresthesia) and flushing are documented to occur in up to 10 out of every 100 users. Official product information notes these effects are typically transient (short-lasting).

Q: Can Sumatriptan Aurobindo be taken with over-the-counter pain relievers?

A: Regulatory documents do not list common over-the-counter (OTC) pain relievers as formally contraindicated combinations. However, the medicine is formally prohibited from being combined with other triptans or ergotamine-type drugs, and official product information does note an increased risk of adverse effects when combining it with certain herbal preparations.

Q: What does the research say about the effectiveness of Sumatriptan Aurobindo?

A: Research, including clinical trials, suggests that the use of the medication is associated with achieving pain-free status or significant headache relief within two hours more often than a placebo. Relief of associated symptoms, such as nausea and sensitivity to light and sound, was also observed in approximately half of the participants in these studies.

Q: What is meant by 'medication-overuse headache'?

A: Official regulatory warnings associated with using acute migraine treatments too frequently note the risk of developing Medication-Overuse Headache (MOH). This is described as a headache that may result from the medicine being used on 10 or more days per month over a prolonged period.

Q: How long do the effects of Sumatriptan Aurobindo usually last?

A: Drug monographs describe the medicine's elimination half-life—the time it takes for half the drug to be removed from the body—as approximately 2.5 hours. Official dosing protocols require a minimum of two hours between doses if a second dose is needed, reflecting the speed at which the medicine is processed by the body.

Q: Are there different forms of Sumatriptan Aurobindo available?

A: Sumatriptan Aurobindo is available as an oral film-coated tablet in multiple strengths. While the active ingredient, sumatriptan, is manufactured by various companies in forms like injections or nasal sprays, the Aurobindo brand itself is specifically provided as an oral tablet.

Q: What are the main findings from major clinical trials of sumatriptan?

A: Major clinical trials indicated that sumatriptan significantly increased the proportion of participants who achieved both pain-free status and overall headache relief compared to placebo. A key finding was the relief of symptoms commonly associated with migraine, such as nausea and sensitivity to light and sound, within two hours of administration.

Q: Are there differences in side effects between the tablet and injection forms?

A: Official documents state that adverse effects are generally similar across the different administration forms, such as the tablet and injection. However, non-oral routes may have unique effects related to the site of administration, such as a localized injection-site reaction.

Q: Is there a maximum number of days a month this medicine should be used?

A: The FDA label notes that the safety of treating an average of more than four headaches in a 30-day period has not been established. This guidance helps address the risk of developing Medication-Overuse Headache associated with using acute treatments too frequently.

Q: Why is this drug sometimes described as a 'rescue' treatment?

A: The medicine is officially indicated for the acute treatment of a migraine attack once symptoms have begun. This therapeutic classification means the drug is intended to quickly interrupt a current episode, rather than being used daily to prevent future episodes from occurring.

Q: Can men and women expect similar results from Sumatriptan Aurobindo?

A: Clinical efficacy trials for sumatriptan have examined the effects of various patient factors on treatment outcome. Official labeling notes that the efficacy of sumatriptan tablets was found to be unaffected by the gender of the subject in these studies.

Q: Is Sumatriptan Aurobindo a generic or a brand-name drug?

A: Sumatriptan Aurobindo is classified as a prescription-only generic medication. It contains the active drug sumatriptan succinate, which is the same active ingredient found in the original brand-name formulation.

Q: Are there specific symptoms that mean I should not take Sumatriptan Aurobindo?

A: The formal contraindications for this medicine are primarily based on a patient's established medical history, such as certain heart conditions or prior stroke. The official labeling does not list general symptoms of a current typical migraine attack (like the presence of aura) as a reason to avoid treatment, except in cases of specific rare migraine types like hemiplegic or basilar migraine.

Q: Can I experience withdrawal symptoms if I stop taking Sumatriptan Aurobindo?

A: Abrupt cessation of frequent triptan use is associated with the development of Medication-Overuse Headache (MOH), sometimes referred to as a rebound headache. The symptoms of MOH often involve an exacerbation of headache, which may also be associated with other symptoms like nausea or sleep disturbance.

Q: What are the official guidelines regarding combining Sumatriptan Aurobindo with other triptans?

A: Official guidelines formally prohibit the co-administration of this medicine with any other 5-HT1 receptor agonist, which includes all other triptans. Doses must be separated by a minimum interval of 24 hours to avoid the risk of additive vasospastic effects.

Q: Is it common for Sumatriptan Aurobindo to cause nausea?

A: Yes, regulatory documentation classifies both nausea and vomiting as common side effects associated with this medication. These effects are documented to occur in up to 10 out of every 100 users.

Q: What is the half-life of sumatriptan as described in drug monographs?

A: According to drug monographs and official labeling, the elimination half-life of oral sumatriptan is approximately 2.5 hours. The half-life is the measure of time required for the amount of drug in the body to be reduced by half.

How to Store and Dispose of Sumatriptan Aurobindo

Storage and disposal must strictly adhere to the conditions mandated in official regulatory labeling.

Required Storage Conditions

Sumatriptan tablets require storage at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F). The permitted temperature range for temporary excursions is 15 C to 30 C (59 F to 86 F). The product must remain stored in its original container.

Safety and Disposal

For child safety, the medicine must be stored out of the reach of children. Regarding disposal, any unused or expired medicinal product or waste material must be discarded in accordance with local requirements established for pharmaceutical waste.